Robertl Kroc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.

06.09.2023 - The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”FDA has cleared the IND for intranasal foralumab, a fully human anti-CD3 monoclonal ... Seite 1

FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease Aug 15, 2023 Isabella Ciccone, MPH Foralumab, a therapy designed to bind to T... -Today at 07:53 am- MarketScreener

Foralumab to advance into Phase 2 human clinical trials using the world’s only fully human intranasal anti-CD3 monoclonal antibodyTrial to be overseen by Brigham and Women’s Hospital, a founding... -Today at 07:00 am- MarketScreener

Webinar to take place on Monday, June 5, 2023 at 12:30 PM ETNEW YORK, May 25, 2023) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes